Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217678 · ClinicalTrials.gov registry record · Phase 4
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
A Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07217678 is a Phase 4 study of Glaucoma and Ocular Hypertension that is actively recruiting participants, run by University of Miami. The registered enrollment target is 20 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07217678, a Phase 4 study of Glaucoma and Ocular Hypertension, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Conditions Studied
Interventions
- DRUG Durysta, Bimatoprost Intracameral Implant 10 µg
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217678
The ClinicalTrials.gov registry entry for NCT07217678 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Durysta, Bimatoprost Intracameral Implant 10 µg is the first listed.
NCT07217678 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07217678 about?
NCT07217678 is a clinical study titled "Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use". The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
What is the current status of trial NCT07217678?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-02-09. Estimated completion is 2028-01-31.
What conditions does trial NCT07217678 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension, Open Angle Glaucoma, Glaucoma, Suspect.
What interventions are being tested in trial NCT07217678?
The interventions under investigation include: Durysta, Bimatoprost Intracameral Implant 10 µg (DRUG).
Who is sponsoring clinical trial NCT07217678?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217678 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.